Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Short-term Investments (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Short-term Investments for 4 consecutive years, with $39.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Short-term Investments rose 1575.91% to $39.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $39.1 million, a 1575.91% increase, with the full-year FY2024 number at $41.1 million, up 904.51% from a year prior.
  • Short-term Investments was $39.1 million for Q3 2025 at Inhibikase Therapeutics, up from $9.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $41.1 million in Q4 2024 to a low of $2.0 million in Q3 2023.
  • A 4-year average of $16.0 million and a median of $15.9 million in 2022 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: tumbled 90.51% in 2023, then surged 1575.91% in 2025.
  • Inhibikase Therapeutics' Short-term Investments stood at $15.9 million in 2022, then tumbled by 74.23% to $4.1 million in 2023, then soared by 904.51% to $41.1 million in 2024, then decreased by 4.87% to $39.1 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Short-term Investments are $39.1 million (Q3 2025), $9.9 million (Q2 2025), and $19.7 million (Q1 2025).